USFDA approves Opdualag to treat metastatic melanoma
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
In contrast to the digital health solutions in the market, TEngage is cloud-based, fully customizable and allows hospitals to implement modules with just the required features, keeping the deployment and operational cost in check
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
Successful proposals will secure fully funded postdoctoral research positions
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
Doctors at Yashoda Hospitals Hyderabad perform rare operation
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Prashant comes with over 17 years of experience in the health, health insurance and other allied healthcare sectors
Subscribe To Our Newsletter & Stay Updated